MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer
Abstract Background Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted i...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12885-025-13509-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585669688426496 |
|---|---|
| author | Kari S. Wagner-Larsen Njål Lura Ankush Gulati Stian Ryste Erlend Hodneland Kristine E. Fasmer Kathrine Woie Bjørn I. Bertelsen Øyvind Salvesen Mari K. Halle Noeska Smit Camilla Krakstad Ingfrid S. Haldorsen |
| author_facet | Kari S. Wagner-Larsen Njål Lura Ankush Gulati Stian Ryste Erlend Hodneland Kristine E. Fasmer Kathrine Woie Bjørn I. Bertelsen Øyvind Salvesen Mari K. Halle Noeska Smit Camilla Krakstad Ingfrid S. Haldorsen |
| author_sort | Kari S. Wagner-Larsen |
| collection | DOAJ |
| description | Abstract Background Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) in LACC patients, and their association with progression-free survival (PFS). Furthermore, to develop, validate, and compare delta- and pretreatment radiomic signatures for prognostic modeling. Methods A total of 110 LACC patients undergoing CCRT with MRI at baseline and mid-treatment were divided into training (cohortT: n = 73) and validation (cohortV: n = 37) cohorts. Radiomic features were extracted from tumors segmented on pre-CCRT and mid-CCRT T2WI and radiomic deltas (delta features) were computed. Two radiomic signatures for predicting PFS were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression: Deltarad (from delta features) and Pre-CCRTrad (from pre-CCRT features). Prognostic performance of the radiomic signatures, 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–IV), and baseline MRI-derived maximum tumor diameter (Tumormax: ≤2 cm; >2 and ≤ 4 cm; >4 cm) was evaluated by area under time-dependent receiver operating characteristics (tdROC) curves (AUC) in cohortT and cohortV (AUCT/AUCV). Mann–Whitney U tests assessed differences in radiomic delta features. PFS was evaluated using the Kaplan–Meier method with log-rank tests. Results Deltarad (AUCT/AUCV: 0.74/0.79) marginally outperformed Pre-CCRTrad (0.72/0.75) for predicting 5-year PFS, and both signatures clearly surpassed that of FIGO (0.61/0.61) and Tumormax (0.58/0.65). In total, four features within Deltarad and Pre-CCRTrad significantly differed in delta feature values between progressors and non-progressors, being consistently lower in progressors (p ≤ 0.03 for all). High Deltarad and Pre-CCRTrad radiomic scores were associated with poor PFS (p ≤ 0.04 for Deltarad in cohortT/Pre-CCRTrad in both cohorts; p = 0.11 for Deltarad in cohortV). Conclusions Delta- and pretreatment radiomic signatures equally allow early prognostication in LACC, outperforming FIGO stage and MRI-assessed maximum tumor diameter. |
| format | Article |
| id | doaj-art-cdb979231db94d158bb00ded609ae423 |
| institution | Kabale University |
| issn | 1471-2407 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj-art-cdb979231db94d158bb00ded609ae4232025-01-26T12:37:49ZengBMCBMC Cancer1471-24072025-01-0125111510.1186/s12885-025-13509-1MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancerKari S. Wagner-Larsen0Njål Lura1Ankush Gulati2Stian Ryste3Erlend Hodneland4Kristine E. Fasmer5Kathrine Woie6Bjørn I. Bertelsen7Øyvind Salvesen8Mari K. Halle9Noeska Smit10Camilla Krakstad11Ingfrid S. Haldorsen12Mohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalDepartment of Obstetrics and Gynecology, Haukeland University HospitalDepartment of Pathology, Haukeland University HospitalClinical Research Unit, Department of Clinical and Molecular Medicine, Norwegian University of Science and TechnologyDepartment of Obstetrics and Gynecology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalDepartment of Obstetrics and Gynecology, Haukeland University HospitalMohn Medical Imaging and Visualization Centre (MMIV), Department of Radiology, Haukeland University HospitalAbstract Background Effective diagnostic tools for prompt identification of high-risk locally advanced cervical cancer (LACC) patients are needed to facilitate early, individualized treatment. The aim of this work was to assess temporal changes in tumor radiomics (delta radiomics) from T2-weighted imaging (T2WI) during concurrent chemoradiotherapy (CCRT) in LACC patients, and their association with progression-free survival (PFS). Furthermore, to develop, validate, and compare delta- and pretreatment radiomic signatures for prognostic modeling. Methods A total of 110 LACC patients undergoing CCRT with MRI at baseline and mid-treatment were divided into training (cohortT: n = 73) and validation (cohortV: n = 37) cohorts. Radiomic features were extracted from tumors segmented on pre-CCRT and mid-CCRT T2WI and radiomic deltas (delta features) were computed. Two radiomic signatures for predicting PFS were constructed by least absolute shrinkage and selection operator (LASSO) Cox regression: Deltarad (from delta features) and Pre-CCRTrad (from pre-CCRT features). Prognostic performance of the radiomic signatures, 2018 International Federation of Gynecology and Obstetrics (FIGO) stage (I–IV), and baseline MRI-derived maximum tumor diameter (Tumormax: ≤2 cm; >2 and ≤ 4 cm; >4 cm) was evaluated by area under time-dependent receiver operating characteristics (tdROC) curves (AUC) in cohortT and cohortV (AUCT/AUCV). Mann–Whitney U tests assessed differences in radiomic delta features. PFS was evaluated using the Kaplan–Meier method with log-rank tests. Results Deltarad (AUCT/AUCV: 0.74/0.79) marginally outperformed Pre-CCRTrad (0.72/0.75) for predicting 5-year PFS, and both signatures clearly surpassed that of FIGO (0.61/0.61) and Tumormax (0.58/0.65). In total, four features within Deltarad and Pre-CCRTrad significantly differed in delta feature values between progressors and non-progressors, being consistently lower in progressors (p ≤ 0.03 for all). High Deltarad and Pre-CCRTrad radiomic scores were associated with poor PFS (p ≤ 0.04 for Deltarad in cohortT/Pre-CCRTrad in both cohorts; p = 0.11 for Deltarad in cohortV). Conclusions Delta- and pretreatment radiomic signatures equally allow early prognostication in LACC, outperforming FIGO stage and MRI-assessed maximum tumor diameter.https://doi.org/10.1186/s12885-025-13509-1Uterine cervical neoplasmsChemoradiotherapyMagnetic resonance imagingDelta-radiomicsRadiomics |
| spellingShingle | Kari S. Wagner-Larsen Njål Lura Ankush Gulati Stian Ryste Erlend Hodneland Kristine E. Fasmer Kathrine Woie Bjørn I. Bertelsen Øyvind Salvesen Mari K. Halle Noeska Smit Camilla Krakstad Ingfrid S. Haldorsen MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer BMC Cancer Uterine cervical neoplasms Chemoradiotherapy Magnetic resonance imaging Delta-radiomics Radiomics |
| title | MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| title_full | MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| title_fullStr | MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| title_full_unstemmed | MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| title_short | MRI delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| title_sort | mri delta radiomics during chemoradiotherapy for prognostication in locally advanced cervical cancer |
| topic | Uterine cervical neoplasms Chemoradiotherapy Magnetic resonance imaging Delta-radiomics Radiomics |
| url | https://doi.org/10.1186/s12885-025-13509-1 |
| work_keys_str_mv | AT kariswagnerlarsen mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT njallura mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT ankushgulati mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT stianryste mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT erlendhodneland mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT kristineefasmer mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT kathrinewoie mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT bjørnibertelsen mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT øyvindsalvesen mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT marikhalle mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT noeskasmit mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT camillakrakstad mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer AT ingfridshaldorsen mrideltaradiomicsduringchemoradiotherapyforprognosticationinlocallyadvancedcervicalcancer |